Clofarabine and Treosulfan as Conditioning for Matched Related and Unrelated Hematopoietic Stem Cell Transplantation: Results from the Clo3o Phase II Trial.
Allogeneic hematopoietic stem cell transplantation
Clofarabine
Treosulfan
Journal
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
ISSN: 1523-6536
Titre abrégé: Biol Blood Marrow Transplant
Pays: United States
ID NLM: 9600628
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
14
05
2019
revised:
17
09
2019
accepted:
30
09
2019
pubmed:
13
10
2019
medline:
24
6
2021
entrez:
13
10
2019
Statut:
ppublish
Résumé
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) can be curative for patients with hematologic malignancies. The ideal conditioning regimen before allo-HSCT has not been established. We conducted a Phase II study to evaluate the tolerability and efficacy of clofarabine and treosulfan as conditioning regimen before allo-HSCT. The primary objective was to evaluate the cumulative incidence of nonrelapse mortality (NRM) on day +100. Forty-four patients (36 with acute myelogenous leukemia, 5 with acute lymphoblastic leukemia, 3 with myelodysplastic syndromes) were enrolled. The median patient age was 47 years, and the median duration of follow-up was 27 months. The conditioning regimen was based on clofarabine 40 mg/m
Identifiants
pubmed: 31605823
pii: S1083-8791(19)30651-2
doi: 10.1016/j.bbmt.2019.09.032
pii:
doi:
Substances chimiques
Clofarabine
762RDY0Y2H
treosulfan
CO61ER3EPI
Busulfan
G1LN9045DK
Types de publication
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
316-322Informations de copyright
Copyright © 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.